Literature DB >> 24153133

Detection of resistance to beta-lactamase inhibitors in strains with CTX-M beta-lactamases: a multicenter external proficiency study using a well-defined collection of Escherichia coli strains.

Aida Ripoll1, Juan-Carlos Galán, Cristina Rodríguez, Nuria Tormo, Concepción Gimeno, Fernando Baquero, Luis Martínez-Martínez, Rafael Cantón.   

Abstract

Under the auspices of the Spanish Society for Infectious Diseases and Clinical Microbiology Quality Control program, 14 Escherichia coli strains masked as blood culture isolates were sent to 68 clinical microbiology laboratories for antimicrobial susceptibility testing to β-lactam antibiotics. This collection included three control strains (E. coli ATCC 25922, an IRT-2 producer, and a CMY-2 producer), six isogenic strains with or without the OmpF porin and expressing CTX-M β-lactamases (CTX-M-1, CTX-M-15, and CTX-M-14), one strain carrying a double mechanism for β-lactam resistance (i.e., carrying CTX-M-15 and OXA-1 enzymes), and four strains carrying CTX-M variants with different levels of resistance to β-lactams and β-lactam-β-lactamase inhibitor (BLBLI) combinations. The main objective of the study was to ascertain how these variants with reduced susceptibilities to BLBLIs are identified in clinical microbiology laboratories. CTX-M variants with high resistance to BLBLIs were mainly identified as inhibitor-resistant TEM (IRT) enzymes (68.0%); however, isogenic CTX-M mutant strains with reduced susceptibilities to BLBLIs and cephalosporins were mainly associated with extended-spectrum β-lactamase production alone (51 to 80%) or in combination with other mechanisms (14 to 31%). Concerning all β-lactams tested, the overall interpretative discrepancy rate was 11.5%, of which 38.1% were the consequence of postreading changes in the clinical categories when a resistance mechanism was inferred. Therefore, failure to recognize these complex phenotypes might contribute to an explanation of their apparent absence in the clinical setting and might lead to inadequate drug treatment selection. A proposal for improving recognition is to adhere strictly to the current CLSI or EUCAST guidelines for detecting reduced susceptibility to BLBLI combinations, without any interpretative modification.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24153133      PMCID: PMC3911446          DOI: 10.1128/JCM.02340-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

Review 1.  [Recommendations from MENSURA for selection of antimicrobial agents for susceptibility testing and criteria for the interpretation of antibiograms].

Authors: 
Journal:  Rev Esp Quimioter       Date:  2000-03       Impact factor: 1.553

2.  Epidemiological survey of amoxicillin-clavulanate resistance and corresponding molecular mechanisms in Escherichia coli isolates in France: new genetic features of bla(TEM) genes.

Authors:  V Leflon-Guibout; V Speldooren; B Heym; M Nicolas-Chanoine
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Emergence of an inhibitor-resistant beta-lactamase (SHV-10) derived from an SHV-5 variant.

Authors:  E E Prinarakis; V Miriagou; E Tzelepi; M Gazouli; L S Tzouvelekis
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

4.  Resistance to beta-lactam/clavulanate.

Authors:  J L Martinez; E Cercenado; M Rodriguez-Creixems; M F Vincente-Perez; A Delgado-Iribarren; F Baquero
Journal:  Lancet       Date:  1987-12-19       Impact factor: 79.321

Review 5.  Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae.

Authors:  N D Hanson; C C Sanders
Journal:  Curr Pharm Des       Date:  1999-11       Impact factor: 3.116

6.  The leucine-responsive regulatory protein of Escherichia coli negatively regulates transcription of ompC and micF and positively regulates translation of ompF.

Authors:  M Ferrario; B R Ernsting; D W Borst; D E Wiese; R M Blumenthal; R G Matthews
Journal:  J Bacteriol       Date:  1995-01       Impact factor: 3.490

7.  Kanamycin-resistant vectors that are analogues of plasmids pUC8, pUC9, pEMBL8 and pEMBL9.

Authors:  B G Spratt; P J Hedge; S te Heesen; A Edelman; J K Broome-Smith
Journal:  Gene       Date:  1986       Impact factor: 3.688

8.  Expression of outer membrane proteins in Escherichia coli growing at acid pH.

Authors:  M Sato; K Machida; E Arikado; H Saito; T Kakegawa; H Kobayashi
Journal:  Appl Environ Microbiol       Date:  2000-03       Impact factor: 4.792

9.  Quality control for beta-lactam susceptibility testing with a well-defined collection of Enterobacteriaceae and Pseudomonas aeruginosa strains in Spain.

Authors:  Rafael Cantón; Elena Loza; María Del Carmen Conejo; Fernando Baquero; Luis Martínez-Martínez
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

10.  Variety of beta-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States.

Authors:  Keith S Kaye; Howard S Gold; Mitchell J Schwaber; Lata Venkataraman; Youlin Qi; Paola C De Girolami; Matthew H Samore; Greg Anderson; J Kamile Rasheed; Fred C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more
  6 in total

1.  Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.

Authors:  Erin E Gill; Octavio L Franco; Robert E W Hancock
Journal:  Chem Biol Drug Des       Date:  2015-01       Impact factor: 2.817

2.  CTX-M-190, a Novel β-Lactamase Resistant to Tazobactam and Sulbactam, Identified in an Escherichia coli Clinical Isolate.

Authors:  Zhen Shen; Baixing Ding; Yingmin Bi; Shi Wu; Su Xu; Xiaogang Xu; Qinglan Guo; Minggui Wang
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

3.  Evolutionary Trajectories toward High-Level β-Lactam/β-Lactamase Inhibitor Resistance in the Presence of Multiple β-Lactamases.

Authors:  Fredrika Rajer; Lisa Allander; Philip A Karlsson; Linus Sandegren
Journal:  Antimicrob Agents Chemother       Date:  2022-06-02       Impact factor: 5.938

4.  Identifying Oxacillinase-48 Carbapenemase Inhibitors Using DNA-Encoded Chemical Libraries.

Authors:  Doris Mia Taylor; Justin Anglin; Suhyeorn Park; Melek N Ucisik; John C Faver; Nicholas Simmons; Zhuang Jin; Murugesan Palaniappan; Pranavanand Nyshadham; Feng Li; James Campbell; Liya Hu; Banumathi Sankaran; B V Venkataram Prasad; Hongbing Huang; Martin M Matzuk; Timothy Palzkill
Journal:  ACS Infect Dis       Date:  2020-03-25       Impact factor: 5.084

5.  Epidemiology of CTX-M-type extended-spectrum beta-lactamase (ESBL)-producing nosocomial -Escherichia coli infection in China.

Authors:  Huiqing Shi; Fengjun Sun; Jianhong Chen; Qianyi Ou; Wei Feng; Xiaolan Yong; Peiyuan Xia
Journal:  Ann Clin Microbiol Antimicrob       Date:  2015-01-16       Impact factor: 3.944

Review 6.  Escherichia coli β-Lactamases: What Really Matters.

Authors:  Priyanka Bajaj; Nambram S Singh; Jugsharan S Virdi
Journal:  Front Microbiol       Date:  2016-03-30       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.